CANNIBICS PHARMACEUT (CNBX)

0.72 -0.04 ( -4.95% ) Oct 21

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

CNBX Detailed Quote

Last Trade:   0.72
Trade Time:   3:55pm
Change:   -0.04
Perc Change:   -4.95%
Prev Close:   0.76
Open:   0.75
Day's Range:   0.71 - 0.77
Bid:   N/A
EPS   -0.01
52wk Range:   0.18 - 7.60
Volume:   217097
Avg Vol:   264920
Market Cap:   85.19M
P/E (ttm):   N/A
PES (ttm):   -0.01
Ask:   N/A

CNBX Recent Headlines

  • Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells 09/25/2017 12:45 PMTEL AVIV, Israel, September 25, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has filed national phase patent applications for its 'System and Method for High Throughput Screening of Cancer Cells' in the United States, Europe, China, India, Brazil, Canada and Australia. The company has filed the national phase applications after having received a favorable international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all the claims innovative and inventive. The proprietary technology patented relates to novel means of personalizing cannabis based treatments of cancer utilizing high throughput screening of biopsies and cell lines treated with pure or crude extracts.
  • Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs 09/06/2017 01:15 PMCannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO) on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs. The method, developed by Cannabics Pharmaceuticals, expands the company's proprietary technology of personalization of cannabinoid medicine.
  • Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells 08/28/2017 06:06 PMTEL-AVIV, Israel, August 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) (CNBX) today announced it received a very positive preliminary international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all claims innovative and inventive. This PCT report is a major step in the progress of the patent application which is now being launched into several major countries and territories. The company is securing its achievements through a very active and expanding patent portfolio.
  • Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics 07/24/2017 12:45 PMCannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research.
  • Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH 07/12/2017 12:45 PMCannabics Pharmaceuticals Inc. (CNBX) today announced it has executed a Collaboration Agreement with SIMFO GmbH, a world leader in cancer diagnostics and liquid biopsies located in Germany. Under the Agreement, Cannabics Pharmaceuticals shall be the exclusive global provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids. The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids (e.g.

FIND OUT HOW MUCH MOMENTUM IS DRIVING YOUR MARIJUANA STOCK!

AS SEEN ON
>>